AGAbdoreza Ghoreishi

Abdoreza Ghoreishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abdoreza Ghoreishi has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intravenous Thrombolysis for Acute Ischemic Stroke Across the Middle East and North Africa (2021–2023): Results from the SITS-MENA Registry

    by Maria Khan, Marius Matusevicius, Suhail AlRukn, Abdoreza Ghoreishi, Mehdi Farhoudi, Elyar Sadeghi Hokmabadi, Payam Sariaslani, Tamer Roushdy, Naveed Akhtar, Yahia Imam, et al.

    Background: Intravenous thrombolysis (IVT) for acute ischemic stroke in the Middle-East and North African (MENA) countries has increased in the last decade, but long-term outcomes and quality of care are less well studied. Methods: This was a prospective observational study to examine 3-month outcomes of IVT-treated patients in MENA stroke units using the SITS Registry. Findings: There were 2768 patients in MENA and 7163 patents in non-MENA treated with IVT and registered in SITS between August 2021 and September 2023. Compared to non-MENA, MENA patients were younger (65 vs 72 years-old), had higher NIH Stroke Scale scores at baseline (11 vs 9) and shorter door-to-needle times (30 vs 54 min). The most common risk factors in MENA were hypertension (64.9 vs 69.8 %) and diabetes (30.8 vs 20.1%). Functional independence at 3 months was similar (56.6% vs 57.7%); however, mortality at 7 and 30 days was significantly higher in MENA (8.3% vs 5.3% and 20.7 vs 14.5%). Symptomatic intracranial hemorrhage rates were low in both groups (<1.2% per SITS-MOST). Early mortality rates related to stroke were comparable (56.7 vs 59.2%) but early deaths caused by myocardial infarction, pneumonia, pulmonary embolism and sepsis were more frequent in MENA (14.2 vs 4.6%, 6.7 vs 4.6%, 1.5 vs 0.4% and 3 vs 1.8%). Interpretation: The overall mortality of IVT-treated patients was increased in MENA at 7 and 90 days post-stroke. Differences in risk factors at baseline may account for mortality but the treatment of medical complications in MENA stroke units warrants further study.

  • Open Access

    Thrombolysis Treatment in Patients Who Are Awake and Have an Unknown Duration of Stroke Receiving Effective and Safe Treatment or Who Are Futile and At Risk: A Study-Based SITS

    by Abdoreza Ghoreishi, Hamideh Nasiri, Fatemeh Karami Zarandi, Kaveh Hadiloo

    Background: Stroke is a leading cause of death worldwide, with approximately 800,000 new cases and 140,000 deaths annually in the United States. Intravenous tissue plasminogen activator (IV tPA) is the standard treatment for acute ischemic stroke (AIS) within a 4.5-hour window. Wake-up stroke (WUS), where the exact onset time is unknown, poses ...

  • Open Access

    Cefaly Neurostimulation Therapy For Intractable Migraine Patients

    by Mahdi Ahani, Pouya Karami, Tina Ehrami, Abdoreza Ghoreishi

    Background and Objective: Migraine is a common neurological disorder affecting one billion people worldwide, causing disability, reduced quality of life, and high economic costs. Medical treatments have often limited efficacy and side effects. Non-pharmacological options such as trigeminal nerve stimulation with devices such as Cefaly® offer alternatives. This study assesses effectiveness ...

  • Identification of four novel mutations in VSP13A in Iranian patients with Chorea-acanthocytosis (ChAc)

    by Vadieh Ghodsinezhad, Abdoreza Ghoreishi, Mohammad Rohani, Mahdi Dadfar, Akbar Mohammadzadeh, Ali Rostami, Hamzeh Rahimi

    Chorea-acanthocytosis (ChAc) is a rare autosomal recessive neurodegenerative disorder characterized by a variety of involuntary movements, predominantly ch


  • IL-38 as an early predictor of the ischemic stroke prognosis

    by Maryam Zare Rafie, Abdolreza Esmaeilzadeh, Abdolreza Ghoreishi, Safa Tahmasebi, Elham Faghihzadeh, Reza Elahi


  • Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative

    by Payam Sasanejad, Leila Afshar Hezarkhani, Shahram Arsang-Jang, Georgios Tsivgoulis, Abdoreza Ghoreishi, Kristian Barlinn, Jan Rahmig, Mehdi Farhoudi, Elyar Sadeghi Hokmabadi, Afshin Borhani-Haghighi, et al.


  • Biofeedback: An Effective Add-on Treatment for Migraine Headache Alongside Medication Therapy

    by Mohammad Reza Hossein Tehrani, Abolfazl Ghoreishi, Abdoreza Ghoreishi, Kalhor Kalhor, Alireza Khosravi

    Background & Objective: Migraine is an occasional headache that represents neurological and gastrointestinal symptoms, as well as changes in the autonomic nervous system. Biofeedback is a non-pharmacological technique used to treat migraine headaches and is proven to reduce headaches and improve performance. The present study aimed to compare the efficacy of ...


  • Open Access

    The association between serum 25-hydroxyvitamin D level and subclinical atherosclerosis in healthy population

    by Vida Mohammadzadeh, Masoud Mehrpour, Abdoreza Ghoreishi, Koorosh Kamali, Babak Zamani

    Background: Subclinical atherosclerosis is the asymptomatic phase of carotid atherosclerosis, and its early diagnosis is important to prevent cerebrovascular diseases. Although the vitamin D plays a role in the structure of vessels, the association between the serum level of vitamin D and subclinical atherosclerosis has not been well-studied. We aimed to investigate the association between serum vitamin D level and carotid artery intima-media thickness (CIMT) in Iranian population. Methods: One hundred individuals with the age range from 20 to 50 years with no history of cardiovascular risk factors were selected for the analysis. Measurements of serum 25-hydroxyvitamin D3 [25(OH) D3] concentration and CIMT were made. Confounding factors such as diabetes, hypertension (HTN), smoking, alcohol, tobacco, dyslipidemia, cardiovascular disease (CVD), high body mass index (BMI), history of drug intake especially calcium, vitamin D, statins, and anti-hypertensive drugs were considered and then excluded from our study. Results: The mean serum vitamin D level was 15.55 ± 0.42 ng/ml, whereas in the increased intima-media thickness (IMT), it was 12.50 ± 9.50 ng/ml. 55% of the subjects were diagnosed with subclinical atherosclerosis (IMT ≥ 0.75 mm). Mean IMT was 0.74 ± 0.12 mm; however, it was higher (0.86 ± 0.30) in severe vitamin D deficiency group. The analysis showed an association between serum 25(OH) D3 level and CIMT (P = 0.002). 44% of those participants with subclinical atherosclerosis had also a severe vitamin D deficiency, while only 13% of normal people had a severe vitamin D deficiency. Also, a correlation was observed between severe vitamin D deficiency and the presence of plaque or higher IMT. Conclusion: Serum 25(OH) D3 level was inversely correlated with CIMT in our investigated subjects with no cardiovascular risk factor.


  • Open Access

    Effect of Nanomicelle Curcumin on Quality of Life and Sleep in Patients With Parkinson’s Disease: A Double-Blind, Randomized, and PlaceboControlled Trial

    by Mehdi Maghbooli, Bahareh Safarnejad, Hossein Mostafavi, Saeideh Mazloomzadeh, Abdoreza Ghoreishi

    Background: Considering the evidence indicating the neuronal protective effects of curcumin in previous studies, this double-blind, randomized, placebo-controlled, and parallel-group trial was aimed at exploring the possible nanomicelle curcumin (SinaCurcumin®, nano-micellar soft gel)- mediated impact on sleep, fatigue, and quality of life (QoL) in patients with Parkinson’s disease (PD). Methods: A sample of 50 PD patients were recruited and randomly divided into experimental (25) and control groups (25). Sleep quality, fatigue, and QoL were assessed based on the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and the Parkinson’s Disease Questionnaire–39 (PDQ-39), respectively, at the beginning and the end of the study. The groups were treated for three months by 80 mg of nano-micellar soft gel twice a day. Results: Nanomicelle curcumin significantly increased sleep quality and QoL compared with placebo (P values=0.0001 and 0.0002, respectively) in PD patients. This significant difference has not influenced by the duration of the disease, the severity of disease progression (Hoehn & Yahr scale), and the cumulative dose of levodopa. This supplement did not have a significant effect on the fatigue severity of patients compared to placebo. Conclusion: It has proposed that the nanomicelle curcumin can be used to improve sleep quality and QoL in PD patients.


  • Open Access

    Impaired oxidative-antioxidative balance during migraine attack

    by Alireza Khosravi, Alireza Nakhaee, Abdoreza Ghoreishi, Zahra Arefpoor, Masoud Sadeghi

    Background: Recent evidence has suggested that oxidative stress may play a role in the pathophysiology of migraine. In this study, we aimed to evaluate the oxidative-antioxidative status in sera of migraine patients from an Iranian population during migraine attacks. Methods: This study recruited 46 migraine patients with or without aura and 45 sex- and age-matched healthy controls. The levels of protein carbonyl (PC), malondialdehyde (MDA) and total oxidants status (TOS) were measured as the indicators of oxidative stress. The levels of total thiols (T-SH), reduced glutathione (GSH) and total antioxidant capacity (TAC) were determined as markers of antioxidant status. Oxidative stress index (OSI) was calculated by dividing TOS to TAC. Results: The serum levels of MDA (4.10 +/- 0.70 vs. 3.20 +/- 0.62, P = 0.003), TOS (18.46 +/- 4.06 vs. 16.21 +/- 3.67, P = 0.007) and OSI (1.54 +/- 0.60 vs. 1.22 +/- 0.46, P = 0.006) were significantly higher in migraine group compared to controls, however, no statistically significant differences of PC levels were found between migraine patients and controls (0.615 +/- 0.161 vs. 0.517 +/- 0.126, P = 0.1). In contrast, the levels of T-SH (273 +/- 51.71 vs. 310.88 +/- 53.32, P = 0.001), GSH (28.08 +/- 6.20 vs. 32.13 +/- 5.8, P = 0.002) and TAC (1.27 +/- 0.226 vs. 1.41 +/- 0.26, P = 0.01) were significantly lower in migraine patients compared to healthy controls. Conclusion: Our study showed higher levels of oxidative stress and lower levels of antioxidant status in migraine group compared to controls, which indicates the possible role of oxidative stress in triggering migraine attacks.